Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

被引：106

作者：

Coletta, AP ^{[1
]}

Clark, AL ^{[1
]}

Banarjee, P ^{[1
]}

Cleland, JGF ^{[1
]}

机构：

[1] Univ Hull, Dept Acad Cardiol, Castle Hill Hosp, Kingston Upon Hull HU15 5JQ, Yorks, England

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2002年 / 4卷 / 04期

关键词：

heart failure; RENEWAL; RENAISSANCE; RECOVER; ATTACH; tumour necrosis factor (TNF);

D O I：

10.1016/S1388-9842(02)00121-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This article continues a series of reports on recent research developments in the field of heart failure. Reports of two key presentations made at the European Society of Cardiology Heart Failure Update meeting held in Oslo, Norway from 8 to 11 June 2002, are included in this article. Summaries of the results of the RENEWAL (RENAISSANCE and RECOVER) and ATTACH studies, presented at the Hot Line sessions held during the meeting are reported. (C) 2002 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved.

引用

页码：559 / 561

页数：3

共 10 条

[1] A glossary of circulating cytokines in chronic heart failure [J].

Adamopoulos, S ;

Parissis, JT ;

Kremastinos, DT .

EUROPEAN JOURNAL OF HEART FAILURE, 2001, 3 (05) :517-526

[2] Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure [J].

Bozkurt, B ;

Torre-Amione, G ;

Warren, MS ;

Whitmore, J ;

Soran, OZ ;

Feldman, AM ;

Mann, DL .

CIRCULATION, 2001, 103 (08) :1044-1047

[3] For debate - Preventing atherosclerotic events with aspirin [J].

Cleland, JGF .

BMJ-BRITISH MEDICAL JOURNAL, 2002, 324 (7329) :103-105

[4] How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey [J].

Cleland, JGF .

EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (03) :243-247

[5] Is aspirin "the weakest link" in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease [J].

Cleland, JGF .

PROGRESS IN CARDIOVASCULAR DISEASES, 2002, 44 (04) :275-292

[6] Safety and efficacy of a soluble P75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure [J].

Deswal, A ;

Bozkurt, B ;

Seta, Y ;

Parilti-Eiswirth, S ;

Hayes, FA ;

Blosch, C ;

Mann, DL .

CIRCULATION, 1999, 99 (25) :3224-3226

[7] Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure [J].

Fichtlscherer, S ;

Rössig, L ;

Breuer, S ;

Vasa, M ;

Dimmeler, S ;

Zeiher, AM .

CIRCULATION, 2001, 104 (25) :3023-3025

[8]

JONES CG, 1999, EUR J HEART FAIL, V1, P425, DOI DOI 10.1016/S1388-9842(99)00059-8

[9] Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure [J].

Packer, M .

JOURNAL OF CARDIAC FAILURE, 2001, 7 (02) :176-182

[10] How are cytokines activated in heart failure? [J].

Paulus, WJ .

EUROPEAN JOURNAL OF HEART FAILURE, 1999, 1 (04) :309-312

← 1 →